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We have developed a novel structure-based evaluation for missense variants that explicitly
models protein structure and amino acid properties to predict the likelihood that a variant
disrupts protein function. A structural disruption score (SDS) is introduced as a measure
to depict the likelihood that a case variant is functional. The score is constructed using
characteristics that distinguish between causal and neutral variants within a group of
proteins. The SDS score is correlated with standard sequence-based deleteriousness,
but shows promise for improving discrimination between neutral and causal variants
at less conserved sites. The prediction was performed on 3-dimentional structures of
57 gene products whose homozygous SNPs were identified as case-exclusive variants
in an exome sequencing study of epilepsy disorders. We contrasted the candidate
epilepsy variants with scores for likely benign variants found in the EVS database, and
for positive control variants in the same genes that are suspected to promote a range of
diseases. To derive a characteristic profile of damaging SNPs, we transformed continuous
scores into categorical variables based on the score distribution of each measurement,
collected from all possible SNPs in this protein set, where extreme measures were
assumed to be deleterious. A second epilepsy dataset was used to replicate the findings.
Causal variants tend to receive higher sequence-based deleterious scores, induce larger
physico-chemical changes between amino acid pairs, locate in protein domains, buried
sites or on conserved protein surface clusters, and cause protein destabilization, relative
to negative controls. These measures were agglomerated for each variant. A list of nine
high-priority putative functional variants for epilepsy was generated. Our newly developed
SDS protocol facilitates SNP prioritization for experimental validation.
Keywords: non-synonymous single nucleotide polymorphism, missense mutation, protein structural analysis,
structural disruption score, variant prioritization, epilepsy disorders
INTRODUCTION
Several prediction programs are available to evaluate missense
variants as either deleterious (having a strong functional effect) or
neutral (having no or only a weak functional effect) from the level
of DNA or protein sequence conservation (Cooper and Shendure,
2011). While existing sequence-based damaging scores agree for
the most deleterious variants, predictions for candidate moderate
effect variants identified from sequencing studies are not much
better than chance. Since there is no clear way to truly evaluate the
predictive accuracy of the scores prior to experimental assessment
of function, there is scope for development of orthogonal meth-
ods for variant prioritization. Our study explores the utility of
solely using protein structure-based assessments as a complement
to existing sequence-based scores.
Of the commonly used automatic tools for prediction of vari-
ant deleteriousness, PolyPhen2 (Adzhubei et al., 2010) already
incorporates protein structure information. It uses an iterative
greedy algorithm to select certain features from a restricted
training set, and then takes a Bayesian approach to assign each
variant into one of four effect categories: probably damaging,
possibly damaging, benign, and unknown. However, it does not
perform evaluations on the actual protein structure that each
variant is found in. Rather, PolyPhen2 includes experimentally
derived-structures that are available for ∼10% of the training set.
Although the implementation has high accuracy (73–92%) for the
identification of true positives in cross-validation data, structural
data does not directly contribute to evaluations of novel genes and
it is not clear how efficiently the generalized structural character-
istic rules used by the algorithm can contrast clinically-associated
variants from neutral variants in a diverse gene set.
In this study, we therefore introduce a new approach for assess-
ing the deleteriousness of non-synonymous single nucleotide
polymorphisms (nsSNPs). Our newly developed protocol uses
additional information, that is, protein structure-based assess-
ments applied only where the structural solution is available,
to complement existing sequence-based scores. More specifi-
cally, our evaluation pipeline focuses on functionality of protein
residues derived from 3-dimensional (3D) protein structures. We
also incorporate multiple classes of structural assessment, namely
measures of protein stability, flexibility, protein-protein interac-
tion potential, and small-molecular binding. As several studies
(Capriotti and Altman, 2011; Jordan et al., 2011) have proven
that structural information increases classification accuracy of
SNPs, we hypothesized that by incorporating results from several
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structure-based assessments, it may be possible to generate char-
acteristic profiles that enhance prediction of the degree to which
a candidate rare variant may disrupt protein function, and lead to
disease development.
We applied this newly developed variant assessment protocol
to a set of 57 gene products harboring homozygousmissense vari-
ants, discovered in a recent large-scale exome sequencing study,
that are exclusive to epilepsy patients (Heinzen et al., 2012).
Epilepsy is a highly genetically heterogeneous disease, for which
each likely causal variant is observed in a small fraction of indi-
viduals, likely with variable expressivity and penetrance (Noebels,
2003). As a result, it is difficult to ascertain which variants are
truly responsible for the etiology of disease in individual patients.
None of the case-exclusive variants documented by Heinzen et al.
(2012) had a high enough prevalence to support statistical associ-
ation with the disease, so experimental tests will be needed to filter
putative causal variants. By contrasting the spectrum of struc-
tural features of the case variants with positive control known
causal variants and negative control neutral variants observed
in healthy individuals for the same proteins, we illustrate the
potential for structural assessment to prioritize new variants for
functionalization.
MATERIALS AND METHODS
Our analysis pipeline applied sequence- and structure-based
assessments to missense mutations and their 3D protein struc-
tures to depict the likelihood that a mutation disrupts protein
function. Numerous databases and prediction programs were
used. The flow diagram of the analysis protocol is illustrated in
Figure 1.
GENOMIC DATASET AND CANDIDATE PROTEIN SEQUENCES
The epilepsy-specific amino acid substitutions identified from a
recent exome sequencing study of epilepsy disorders (Heinzen
et al., 2012) served as our case variants for which we aimed to
assess whether or not they are likely to impact protein function.
In that study, exome sequencing was performed on 118 cases and
242 controls. Follow-up genotyping for candidate causal vari-
ants included approximately 90 and 65% of individuals with
European ancestry in the case (n = 878) and control (n = 1830)
groups, respectively (Heinzen et al., 2012). The study identified 72
homozygous variants (68 are nsSNPs) found in 71 genes (“gene
set 1”) that were exclusive to cases. Among these, 52 nsSNPs were
present in more than one affected individual. All genes in this
first dataset had been previously characterized but not known
to cause epilepsy; therefore, we added a second gene set (“gene
set 2”) to represent genes known to associate with the disorders.
We attained the second gene list (n = 41 genes) from two pub-
lic repositories of genetic variations: MSV3d (Luu et al., 2012)
and SwissVar (Mottaz et al., 2010); none of the genes overlap with
entries from the primary dataset. There are 373 missense vari-
ants in the 41 genes that have been documented to cause epilepsy;
therefore, we treated them as case variants for gene set 2.
For both sets of genes, we compiled corresponding nega-
tive neutral and positive causal variants from the EVS database
(retrieved March 2013) (NHLBI Exome Sequencing Project,
2013), and MSV3d (July 2012 release) (Luu et al., 2012) and
SwissVar (accessed February 2013) (Mottaz et al., 2010), respec-
tively. Positive controls are documented non-epileptic disease-
causing nsSNPs found in the same genes (n = 134 nsSNPs from
14 genes of set 1, and n = 205 nsSNPs from 41 genes of set 2).
Likewise, negative controls are variants observed in these genes,
but with no clinical associations (neutral nsSNPs). Any negative
controls already identified as either case or positive SNPs were
excluded from the list of neutral SNPs, resulting in 5281 and 1490
putatively neutral (i.e., negative control) SNPs for sets 1 and 2,
respectively.
GENE AND VARIANT ANNOTATIONS
In order to infer amino acid indices for the altered amino
acid residues, nsSNPs were mapped to their corresponding pro-
tein sequences and structures using transcript IDs. All protein
sequences (major isoforms) were downloaded from the UniProt
database (accessed February 2013) (Uniprot Consortium, 2012).
Prior to applying our new variant analysis protocol, we performed
literature searches on the genes and SNPs in our datasets in order
to manually annotate their influence on the disease. In particu-
lar, we compared the features of gene sets 1 and 2, and recorded
relevant findings.
First we grouped genes by their related biological path-
ways or biological functions using a gene group profiling
method (Reimand et al., 2011). Second, we performed literature
searches using SNPshot—a text mining tool for PubMed abstracts
(accessed December 2012) (Hakenberg et al., 2012). Third, we
assumed that amino acid mutations caused by the rare case SNPs
or the causal SNPs would locate in the vicinity of functional
sites of protein chains. Therefore, we utilized UniProt’s sequence
feature records (accessed February 2013) (Uniprot Consortium,
2012) to check if the mutating amino acids locate in any of
the important sites, e.g., molecule processing sites, binding sites,
modification sites, etc.
Population-specific minor allele frequencies (MAFs) for all
variants were compiled from NHLBI GO Exome Sequencing
Project (ESP6500) (June 2012 release), available from dbNSFP 2.0
(accessed March 2013) (Liu et al., 2011).
PROTEIN STRUCTURE DATASET
We used protein 3D structures to determine the structural nature
of altered protein residues and to evaluate the effects of sin-
gle point mutations introduced by nsSNPs on a specific protein.
To ensure that we represent most of the proteins with high
quality 3D structures, we employed several structural sources.
Experimentally derived structures were retrieved from RCSB
(retrieved April 2013) (Bernstein et al., 1977). Homology mod-
els were compiled from SAHG (retrieved July 2013) (Motono
et al., 2011) or automatically built using Phyre2 (accessed April
2013) (Kelley and Sternberg, 2009). Multiple structural candi-
dates representing an overlapping protein chain were compared
and only one best structure was chosen to represent the best
non-overlapping protein segment.
Details of the two approaches for acquiring protein homol-
ogy models are as follows. First, we searched for 3D models
from the SAHG database (Motono et al., 2011), which contains
a collection of encoded human protein structures, constructed
Frontiers in Genetics | Statistical Genetics and Methodology April 2014 | Volume 5 | Article 82 | 2
Preeprem and Gibson SDS for missense variant assessments
FIGURE 1 | Flow diagram of the analysis pipeline. The analysis employed
sequence-based deleterious prediction scores, parameters which reflect the
nature of amino acid changes, and 3D structure-based evaluations. Structural
analyses were performed by characterizing functionality of mutated protein
residues caused by negative and positive SNPs (indicated by green and red
stick representations, respectively). All analysis results were collectively used
to evaluate enriched features found predominantly in causal SNPs. We then
examined these predictors with regard to the case variants. The number of
deleterious structure predictions per substitution represents a “structural
disruption score” (SDS), and was used to rank candidate epilepsy variants.
by Modeller software (Sali and Blundell, 1993). We downloaded
only structures having >15% sequence identity to the template.
The retrieved proteins exhibit either ligand bound (holo) and/or
unbound (apo) forms. Second, we built protein models by multi-
ple template methodology using the automated Phyre2 homology
modeling server (Kelley and Sternberg, 2009). Structure tem-
plates were selected by default and models were built from vari-
able numbers of high confidence templates. This multi-template
approach ensures that the model covers most of the protein chain.
Large proteins (>1200 amino acids) were truncated into smaller
domain(s) using domain boundary information from Interpro
(Quevillon et al., 2005). A model representing each shortened
sequence was built independently using either the single- or
multi-template method; there was no attempt to join multiple
models into a single model for a protein. For models created with
the Phyre2 server, we retained the best homology model based on
the empirical criteria that >50% of the residues were modeled
at >90% confidence.
After the initial homology model selection, the models were
further subjected to energy minimization with explicit solvent
using the YASARA force field (Krieger et al., 2009) to resolve any
steric conflicts found within the structures. Next, we validated
the homology models using two independent scores: QMEAN6
(Benkert et al., 2009) and ModFOLD4 (McGuffin et al., 2013).
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Both scores show good ability to distinguish between good and
bad models in the recent Critical Assessment of protein Structure
Prediction (CASP) experiments (Kryshtafovych et al., 2014). To
facilitate the structural validation step, we selected structures
that pass the QMEAN6 threshold for subsequent ModFOLD4
evaluations.
In many cases, we initially selected more than one validated
structure to represent an identical protein domain. To retain only
one best representative structure for a protein segment, we used
Chimera (Pettersen et al., 2004) to visualize all structure can-
didates and determined the structural similarity among them
using two parameters: root-mean-square deviation (RMSD) of
Cα atoms, and quality score (Q-score) that normalizes an RMSD
by the alignment length. All measurements were performed with
Chimera’s MatchMaker tool (Pettersen et al., 2004). When sev-
eral overlapping structures agreed with each other, we selected the
one with the best ModFOLD4 score. When the structures were in
disagreement, we discarded them all together. Our retrieval and
validation pipeline for protein 3D structures yielded 114 non-
overlapping structures representing 57 gene products from gene
set 1, and 51 non-overlapping structures representing 36 proteins
from gene set 2.
Table 1 summarizes the number of missense variants from
our genomic dataset in three categories (case, negative, and pos-
itive controls), with respect to the presence/absence of their
corresponding 3D structures.
INFERRING VARIANT DELETERIOUSNESS FROM SEQUENCE-BASED
PREDICTORS
We obtained sequence-based predictions for each amino acid
variant from dbNSFP 2.0 (accessedMarch 2013) (Liu et al., 2011).
The program provides precomputed deleteriousness scores for six
established deleterious prediction algorithms: SIFT (Kumar et al.,
2009), PolyPhen2_HumDiv and PolyPhen2_HumVar (Adzhubei
et al., 2010), LRT (Chun and Fay, 2009), MutationTaster
(Schwarz et al., 2010), and MutationAssessor (Reva et al., 2011).
Three evolutionary conservation-based scores were also included:
GERP++ (Davydov et al., 2010), phyloP (Pollard et al., 2010),
and SiPhy (Lindblad-Toh et al., 2011). For simplicity, we assigned
the level of deleteriousness and conservation to each mutation
based on howmany predictors reported the mutation to be either
“deleterious” (maximum score of 6) or “conserved” (maximum
score of 3).
ADDITIONAL PARAMETERS FOR SEQUENCE-BASED ANALYSIS
In addition to the SNP-based prediction parameters that are
derived from multiple sequence alignments, some useful infor-
mation can be analyzed from a single protein sequence alone. For
example, amino acids with similar physicochemical properties
may substitute for one another while maintaining the function-
ality of the protein. Three indicators may be used to highlight
the most severe changes of amino acid pairs. First, Grantham
scores (Grantham, 1974) reflect the degree of physico-chemical
difference between pairs of amino acids. Second, changes involv-
ing any glycine or proline residues are likely to affect protein
function since these two residues have special roles with regard
to protein structure: proline has an exceptional conformational Ta
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rigidity compared to other amino acids while glycine is much
more conformationally flexible (Gunasekaran et al., 1998). Third,
gain or loss of disulfide bonds occurs when variants induce
changes in cysteine residues. Disulfide bond formation between
non-adjacent cysteines can facilitate protein folding; hence, they
are important for maintaining the structural integrity of the
protein (Darby and Creighton, 1995). In this context, we used
DiANNA webserver (Ferre and Clote, 2006) to predict the disul-
fide connectivity patterns in the wild type protein, and then deter-
mined if the amino acid mutation affects the bonding of cysteine
pairs.
INFERRING VARIANT DELETERIOUSNESS FROM STRUCTURE-BASED
PREDICTORS
A number of currently available protein structural analysis tools
have the potential to be applied to structure-based variant assess-
ment protocols (Verma et al., 2012). To assess the functionality
of mutated protein residues, we concentrated on four features of
structural analysis: protein stability, protein flexibility, protein-
ligand binding potential, and protein-protein interaction poten-
tial. Many mutations disrupt these elements, and as a result,
contribute to disease etiology.
Protein stability
For assessment of protein stability, we aimed to first identify
amino acids with specialized roles in promoting protein stabil-
ity, and second to determine which mutations cause a significant
change in protein stability. For the first objective, we used SCide
webserver (Dosztanyi et al., 1997, 2003) and SRide program
(Magyar et al., 2005) to identify amino acids with essential sta-
bility functions. Long-range stabilization center (SC) residues are
pairs of amino acids having close atomic contact (sum of van
der Waals radii <1Å), but locate at least ten amino acids apart
on the primary sequence (Dosztanyi et al., 1997, 2003). A subset
of SC residues may make distinct contributions to protein sta-
bility because they are also evolutionary conserved and located
in the core region of the protein, and/or have many interact-
ing partners. SC residues with these two extra properties are
referred as stabilizing residues (SRs); they are also expected to
make key contributions to protein stability (Magyar et al., 2005).
For the second objective, we aimed to determine if a partic-
ular mutation affects protein stability by means of inducing a
large magnitude of free energy change (G). For this purpose,
we selected PoPMusic 2.1 (Dehouck et al., 2011) as our G
predictor.
Amino acid changes that increase protein stability (G < 0)
and those associated with the destabilizing mutation (G >
0) are noted. Due to large differences in performance of stabil-
ity change calculations (Khan and Vihinen, 2010), the proper
margin for severe stability change can be ambiguous. However,
it is known that the sensitivity in predicting stabilizing muta-
tions is much less than for destabilizing ones (Worth et al.,
2011), and the correlation between predicted stability change
(GP) and measured values (GM) of our selected pro-
gram is ∼1 kcal/mol (Dehouck et al., 2011). Therefore, in our
study, we followed the suggestions made by Dehouck et al.
(2011). The stability changes are categorized into four levels:
no change if G is between ±0.5 kcal/mol, mildly stabiliz-
ing if G is between −0.5 and −2 kcal/mol, mildly desta-
bilizing if G is between 0.5 and 4 kcal/mol, and strongly
destabilizing if G is ≥4 kcal/mol.
Protein flexibility
Protein flexibility is an important protein feature because highly
dynamic sites are often involved in special functions, such as
binding residues that can undergo subtle motion rearrangements
when a small molecule is bound. Flexible amino acid residues
permit large protein movements during protein folding and con-
formational switches (Teilum et al., 2009). For evaluating the
levels of residue dynamics within a protein, we employed the
predicted B-factors (relative vibrational motion) and root-mean-
square fluctuations (RMSFs) obtained from a prediction pro-
gram PredyFlexy (de Brevern et al., 2012) to classify amino acid
residues into rigid, intermediate, or flexible sites. For predicting
protein movements of higher amplitudes, such as in conforma-
tional switches, we used the program FlexPred (Kuznetsov, 2008;
Kuznetsov and McDuffie, 2008) to determine which amino acid
residues are located at conformationally flexible sites, indicated by
a probability value P(Flexible).
Protein-ligand binding potential
For a SNP that causes an amino acid change in the vicinity of a
catalytic site or a ligand binding site, it is possible to determine
whether the mutation is indeed affecting the catalytic activity or
the ligand binding affinity of the protein. In silico predictions
are possible, but they require extensive computational resources.
We utilized two alternative approaches to predict the ligand
binding sites or catalytic sites from protein 3D structures, and
assessed whether or not the altered protein residues locate in or
near the predictions. The first approach began with the use of
3DLigandSite (Wass et al., 2010) to search for ligands present in
homologous structures. Then, a cluster of amino acids located
within a default distance setting of 0.8 Å of the selected ligand
was predicted as a pocket site, and amino acid residues that make
up that pocket site were specified as ligand binding residues. In
the second method, catalytic sites were predicted by scanning
for protein residues that are not well optimized. This assump-
tion is based on the finding that catalytic sites are generally
designed for function rather than stability (Dehouck et al., 2011).
Low optimality residues are those whose several possible muta-
tions would improve protein stability. The program PoPMusic
(Dehouck et al., 2011) is fast enough that it can calculate stabil-
ity changes (Gs) of all possible mutations at a given position
in the protein sequence, and was used to identify non-optimized
amino acid residues based on the summation of all stabilizing
Gs. This parameter designates the degree of non-optimality
() for each amino acid residue along the protein chain.
Protein-protein interaction potential
Disease-causing mutations that do not occur in binding sites or
buried sites are predominantly found on protein interfaces (David
et al., 2012); therefore, we assessed which of the mutating protein
residues may be involved in this type of inter-molecular interac-
tion. We used PatchFinder program (Nimrod et al., 2005, 2008),
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which evaluates evolutionary conservation scores in conjunc-
tion with solvent accessibility of protein residues, to determine
the most significant cluster of conserved residues on the sur-
face of a protein. This patch indicates possible functional sites of
protein-protein interactions.
ADDITIONAL PARAMETERS FOR STRUCTURE-BASED ANALYSIS
Other information retrieved from the structure-based data
includes the type of protein secondary structure that each vari-
ant interrupts, and the relative solvent accessibility (RSA) of
the altered protein residue. We obtained these predictions from
PoPMusic (Dehouck et al., 2011). Due to the small sample size,
we modified the eight reported types of protein secondary struc-
ture (Kabsch and Sander, 1983) into five groups: (G/H/I), E,
(T/B), S, and C. The 3-, 4-, and 5-turn helices (groups G, H, and
I, respectively) were grouped jointly as helices. Extended strand
in parallel and/or anti-parallel β-sheet remains as an individual
group (group E). Groups T or B correspond to helices or sheets
whose hydrogen bonding patterns are too short to form proper
secondary structures. Lastly, groups S and C denote bend and coil
annotations, respectively.
The RSA for residue X is expressed as a percentage of that
observed for an Alanine-X-Alanine tripeptide. This conformation
would expose the central X residue in the tripeptide as much as
would normally be possible in a protein (Dehouck et al., 2011).
We considered protein residues whose RSA≤ 20% as buried sites.
Otherwise, they are expected to be on the protein surface.
STATISTICAL COMPARISON OF POSITIVE AND NEGATIVE SNPs
We tested which predictions and measures can statistically dis-
tinguish between negative and positive control SNPs from each
gene group. Particularly, we assessed which characteristics are
most likely to be enriched in positive controls, and therefore
imply disruption of functionality. After defining thresholds of
likely deleterious function, we classified the predicted values for
negative and positive controls into each different category. The
categories for structural indicators, the numerical cutoff values,
and the numbers of mutations with extreme values from the two
datasets are summarized in Table 2.
For continuous parameters, we compared the difference
between the means of the positive and negative controls
using two-tailed unpaired t-tests (Table 3). The distributions
of scores within each SNP group were also illustrated by den-
sity plots (Figures 2, 3). For non-numerical characteristics, we
used Fisher’s exact test to determine whether the proportions of
negative and positive control SNPs for each of the features are
significantly different (Table 4). For continuous measures, sim-
ilar analyses were performed after first transforming the scores
into discrete categories based on prespecified thresholds that are
most likely to discriminate normal and aberrant residues. Once a
series of predictions and measures was generated for all possible
variants in a gene set, we converted continuous parameters into
categorical classes, utilizing both literature-based and empirical
cutoff values to represent the extremes (Table 2).
For protein stability and sequence optimality measures, we
followed the suggested thresholds from the PoPMusic program
(Dehouck et al., 2011). Stability changes were classified into four
groups (mildly stabilizing, strongly stabilizing, mildly destabiliz-
ing, and strongly destabilizing) using the aforementioned cutoffs
for G. Regarding sequence optimality, it has been shown that
as the threshold for  becomes more stringent, the proportion
of catalytic sites to other sites increases (Dehouck et al., 2011).
For our analysis, we selected a cutoff for which residues hav-
ing  ≤ −5 kcal/mol are more likely to locate in ligand-binding
domains.
For the remaining continuous measures, i.e., B-factor, RMSF,
and P(Flexibility), we used empirical criteria to define the
extremes. Extreme values for data set 1 and 2 were derived inde-
pendently, but with an identical approach. First, we compared
the score distributions of each measurement, collected from all
possible SNPs in the protein set. Then, we selected the thresh-
olds for each parameter so that we captured a handful of extreme
variants. When applicable, we made sure that our thresholds do
not induce large numbers of misclassifications. In summary, our
empirically-defined thresholds are generally set at the top and
bottom 2.5 percentiles. B-factor and RMSF predictions were clas-
sified into either highly rigid (extreme small negative values)
or highly dynamic (extreme large positive values). Similarly, we
denoted residues as conformationally rigid if the P(Flexibility) is
exceptionally low, or conformationally flexible if the probability
is notably high.
ASSIGNING A STRUCTURAL DISRUPTION SCORE TO CANDIDATE
EPILEPSY VARIANTS
After testing for statistically significant differences between neg-
ative and positive SNPs, we summarized the list of deleterious
structure predictions and examined these predictors with regard
to the case variants. We counted the number of deleterious struc-
ture predictions per substitution and represented this number as
a “structural disruption score” (SDS). The scores were ranked
and candidate epilepsy variants with a score of ≥ 4 out of 7 are
suggested to be “putative structural disrupted variants.” Further
partitioning of this list based on the gene’s tolerance of poly-
morphism, RVIS (Petrovski et al., 2013), yields two subgroups:
variants of high tolerance genes (genes that have more variants
than expected), and variants of low tolerance genes (genes that
have less variants than expected). These two groups of variants are
also discussed in detail with respect to their disease implications.
To examine the contribution of each selected parameter,
especially the sequence-based deleterious score, toward our
SDS, we compared the values of SDS with the Condel com-
posite score (Gonzalez-Perez and Lopez-Bigas, 2011), derived
from three of the deleteriousness measures (SIFT, PolyPhen,
and MutationAssessor). The evaluation was performed with a
step-wise procedure. First, we tested for a correlation between
the Condel score and SDS—including all parameters from the
sequence-based and structure-based predictions (total n parame-
ters). Then, we re-evaluated the correlation using n-1 parameters,
by excluding one of the SDS components at a time.
RESULTS
CANDIDATE GENE AND VARIANT ANNOTATIONS
Despite the fact that Heinzen et al. (2012) performed path-
way analysis on 1183 genes harboring either homo- and/or
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Table 2 | Categories for structural indicators, cutoff values for continuous numerical parameters, and number of SNPs with extreme measures.
Indicators Cutoff # Case (%) (n = 30) # Neg (%) (n = 1674) # Pos (%) (n = 100)
Stability change Stabilizing: G between −2 and −0.5 kcal/mol 0 19 (1%) 0
Strong stabilizing: G ≤ −2 kcal/mol 0 0 0
Destabilizing: G between 0.5 and 4 kcal/mol 20 (65%) 830 (50%) 66 (66%)
Strong destabilizing: G ≥ 4 kcal/mol 0 1 (0%) 0
Dynamic sites Highly rigid : B-factornorm ≤ −0.537 (@2.5%) 0 38 (2%) 3 (3%)
Highly dynamics: B-factornorm ≥ 1.17 (@97.5%) 1 (3%) 44 (3%) 1 (1%)
Dynamic sites Highly rigid : RMSFnorm ≤ −0.607 (@0.5%) 0 48 (3%) 2 (2%)
Highly dynamics: RMSFnorm ≥ 1.195 (@99.5%) 1 (3%) 48 (3%) 3 (3%)
Flexible sites Conformationally rigid : P(Flexible) ≤ 0.158 (@2.5%) 1 (3%) 34 (2%) 2 (2%)
Conformationally flexible: P(Flexible) ≥ 0.860 (@97.5%) 1 (3%) 52 (3%) 0
Sequence optimality Highly non-optimal:  ≤ −5 kcal/mol 1 (3%) 49 (3%) 5 (5%)
All cutoff values were defined exclusively for gene set 1. The counts and percentages of variants with extreme values in each of the three variant classes are
included.
Table 3 | T -test statistics for gene sets 1 and 2.
Parameters Prob > |t|, (t ratio), df†
Set 1 (57 genes) Set 2 (36 genes)
Sequence-based deleterious scores SIFT <0.0001* (6.60) df 1704 <0.0001* (4.61) df 598
PolyPhen2_HDIV <0.0001* (8.15) df 1772 <0.0001* (7.38) df 657
PolyPhen2_HVAR <0.0001* (10.22) df 1772 <0.0001* (8.70) df 657
LRT <0.0001* (4.19) df 1734 0.0066* (2.73) df 654
MutationTaster <0.0001* (9.39) df 1674 <0.0001* (5.57) df 631
MutationAssesssor <0.0001* (15.30) df 1772 <0.0001* (6.06) df 652
Sequence conservation scores GERP <0.0001* (5.30) df 1772 <0.0001* (3.92) df 657
phyloP <0.0001* (4.81) df 1772 0.0010* (3.29) df 657
SiPhy <0.0001* (5.89) df 1771 <0.0001* (4.95) df 657
Structure-based scores G <0.0001* (4.81) df 1772 <0.0001* (3.83) df 657
B-factor 0.0190* (−2.35) df 1756 0.2450 (1.16) df 657
RMSF 0.2304 (−1.20) df 1756 0.2264 (1.21) df 657
P(Flexible) 0.1185 (−1.56) df 1772 0.7594 (−0.31) df 657
 0.9090 (−0.11) df 1772 0.2308 (−1.20) df 657
RSA 0.0035* (−2.93) df 1772 0.0658 (−1.84) df 657
All tests were performed on a subset of SNPs whose protein structures pass quality validations. Significant statistics indicate different means between negative
and positive SNPs.
†Statistic parameters include the two-tailed p-value, value of the t-statistics (t ratio), and the degree of freedom (df). Significant p-values (α = 0.05) are designated
with “*.” The number of “df” equals to n-2 samples used in the analysis.
heterozygous nsSNPs, with a genotype exclusive to the case group,
no significantly over-represented biological pathways were found
(Heinzen et al., 2012). Using an alternative gene group profiling
method (Reimand et al., 2011), we also did not observe a statis-
tical abundance for any biological terms derived from gene set 1.
However, this method did reveal that ∼40% of genes in set 2 have
roles in transmission of nerve impulses, ion channel complexes,
or ion gated channel activity. A text mining method (Hakenberg
et al., 2012) discovered only 1 gene from set 1 that may be
linked to epilepsy. This gene codes for a ubiquitin-like modi-
fier activating enzyme 2 (UBA2), a drug metabolizing enzyme
that plays roles in GABAergic and cholinergic neuronal develop-
ment (Kitamura et al., 2009). Specifically, mutations in ubiquitin
protein ligase along with disruptions in the important neuronal
GABA receptor genes are suggested to induce seizure (Olsen,
2011). By contrast, all genes in set 2 are suspected to be involved
in a wide range of epilepsy disorders (Mottaz et al., 2010; Luu
et al., 2012). Also note that the proportion of variants in cases
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FIGURE 2 | Density plots of six deleterious scores for Case, Neutral,
and Causal SNPs. By most of the standard deleteriousness scores, the
distributions of cases in gene set 1 (Panel A) are closer to the neutral
than the causal variants, and the neutral and causal variants are
significantly different. The “known epilepsy” dataset (gene set 2, Panel
B) demonstrated similar results. In this gene set, variants documented to
cause epilepsy were regarded as “cases,” while variants associated with
other disease types were considered as “causal SNPs (positive control).”
Although three prediction programs (SIFT, Polyphen2_HDIV, and
Polyphen2_HVAR) suggested case and causal SNPs share similar
distributions of deleterious scores, the remaining three programs illustrate
their prediction algorithms do not favor the two types of causal variants
equally. More importantly, case SNPs (epilepsy-causing SNPs) resemble
neutral SNPs more than the causal ones.
relative to controls is much lower for genes in set 1 than in set 2
(Table 1).
Annotation of altered amino acid residues indicated some con-
sistent patterns between case and causal variants. When we per-
formed sequence feature searches (Uniprot Consortium, 2012) to
compute the number of variants localizing in structurally or func-
tionally important sites of a protein chain, we observed that more
than half of the positive SNPs in both gene sets 1 and 2 were
predicted to locate in transmembrane, topological domain, or
repeat regions. Similar patterns were found for the case-exclusive
epilepsy variants.
STATISTICALLY SIGNIFICANT DIFFERENCES BETWEEN POSITIVE AND
NEGATIVE SNPs
Table 3 documents that all deleteriousness scores, all conser-
vation scores, and some of structure-based scores have signif-
icantly different means between negative and positive SNPs.
The single parameters that best differentiate the groups are
the MutationAssesssor prediction for gene set 1 and the
PolyPhen2_HVAR prediction for gene set 2, but more notable is
the highly significant differentiation for all of the sequence-based
scores. Although the t-ratios are consistently lower in set 2 than
set 1, the smaller sample of genes precludes inference that there is
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FIGURE 3 | Density plots for relative solvent accessibility and free
energy change for Case, Neutral, and Causal SNPs. The two
structure-based scores demonstrate that Case and Causal SNPs share similar
characteristics. Results were obtained from two independent sets of genes
(Panels A,B). Note the shift of the blue curves (cases) toward the causal
SNPs (red) and away from the neutral ones (green).
Table 4 | Fisher’s exact test statistics for gene sets 1 and 2.
Enrichment types Significant features Fisher’s exact test (one-tailed)
Set 1 (57 genes)† Set 2 (36 genes)‡
Enriched in causal SNPs Deleterious count ≥ 4 <0.0001* < 0.0001*
Conservation count = 3 Enriched in neutral SNPs < 0.0001*
Induce large amino acid change (Grantham score ≥ 100) <0.0001* < 0.0001*
Induce disulfide change NS (p = 0.6081) < 0.0001*
Induce glycine/proline change 0.0003* < 0.0001*
Locates in buried site (RSA ≤ 20%) 0.0109* < 0.0001*
Locate in conformationally rigid site (P(Flexible) ≤ 0.74) NS (p = 0.0558) 0.0060*
Locate on protein patch <0.0001* < 0.0001*
Locate in protein domain 0.0204* < 0.0001*
Strongly reduce protein stability (G ≥ 4 kcal/mol) NS (p = 1) 0.0400*
Reduce protein stability (G ≥ 0.5 kcal/mol) 0.0009* < 0.0001*
Enriched in neutral SNPs Conservation count = 3 <0.0001* Enriched in causal SNPs
Locate in highly dynamics site (B-factornorm ≥ 97.5%) NS (p = 0.2671) 0.0224*
Locate in highly flexible site (P(Flexible) ≥ 97.5%) 0.0468* NS (p = 0.1432)
High sequence conservation (conservation count = 3) is a feature that enriched in causal SNPs of gene set 2, but is more likely to be found in neutral SNPs of gene
set 1.
†Data for gene set 1 includes 100 causal SNPs and 1674 neutral SNPs.
‡Data for gene set 2 includes 289 causal SNPs (184 epilepsy case variants plus 105 non-epilepsy positive control variants), and 554 neutral SNPs.
Significant p-values (α = 0.05) are designated with “*.” Non-significant test statistics are labeled with NS, followed by the correspondent p-value.
a difference between the two sets. Notably, three of the structure-
based measures are also at least nominally significantly different
between positive and negative control variants in set 1, and trend
in the same direction in set 2: G protein stability, B-factor
protein flexibility, and RSA.
We converted several of the continuous structural measures to
categorical “normal” vs. “extreme” values and compared profiles
of disease causal variants with those of neutral variations in
gene sets 1 and 2. Table 4 reports the list of significantly distinct
sequence/structural features for each variant category based on
Fisher’s exact test. Seven significant characteristics of causal vari-
ants found in the 57 genes in set 1 are: having a high deleterious
count (≥4 out of 6 scores), introducing an amino acid change
with large physico-chemical dissimilarity, inducing glycine or
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proline change, being situated in a protein domain, buried site or
on a conserved protein surface, and causing at least mild protein
destabilization. By contrast, negative control SNPs of this gene
set were found to be enriched in conserved variants (conserva-
tion count = 3 out of 3) and generally locate in conformationally
flexible sites.
These findings were validated with a parallel analysis of gene
set 2, although in this case we gained statistical power by combin-
ing the set of epilepsy case variants with the non-epilepsy positive
control SNPs (combined disease-SNPs n = 289). Each of the sig-
nificant features detected in gene set 1 replicates in set 2, and
additional evidences that disruption of disulfide bonds and loca-
tion in conformationally rigid sites differentiate neutral and dis-
ease variants were obtained. These findings emphasize that causal
variants are likely to affect protein functional sites, a conclusion
that can only be obtained from structure-based analysis.
STRUCTURAL FEATURES PREDICT DELETERIOUSNESS OF CASE SNPs
Next, we asked how the distribution of scores for the putative
epilepsy-case variants compares with the negative and positive
controls. By most of the standard deleteriousness scores, the dis-
tributions of cases are closer to the negative than the positive
controls in both datasets (Figure 2). We conclude that there is lit-
tle evidence from standard measures for enriched deleteriousness
in the case variants from the epilepsy study. Similar observations
were found for Grantham score, protein flexibility parameters,
and a few other structural measures (data not shown).
However, we determined that the solvent accessibility mea-
sure (RSA) and a protein stability measure (G) assign case
variants to be more comparable to positive than negative con-
trols (Figure 3A). Likewise, the same two structural parame-
ters place “known epilepsy” variants in gene set 2 (Figure 3B)
closer to the distribution observed in other disease-causing muta-
tions. This analysis emphasizes the potential for structure-based
deleteriousness measures to generate predictions that are more
discriminating than those derived from measures of sequence
conservation.
To obtain a list of high-priority functional nsSNPs for epilepsy,
we applied the deleterious structure predictions enriched in pos-
itive SNPs (Table 4) to all candidate epilepsy variants and iden-
tified the ones with high SDSs (score ≥4 out of 7). A list of
14 high-likelihood structure-disrupted variants from 30 missense
mutations was generated. To account for differences in the bur-
den of mutations among genes, we used the Residual Variation
Intolerance Score (RVIS) (Petrovski et al., 2013) to identify and
compare the levels of mutational intolerance of each gene in our
two datasets. The parameter determines the deviation of observed
vs. expected numbers of common variants in a gene. Petrovski
et al. (2013) found that genes which carry many common muta-
tions (large positive RVISs) are less likely to influence disease
development. Comparison of average RVIS between genes in sets
1 and 2 indicated that the two groups do not have the same toler-
ance to variations (p-value 0.0011, two-tailed t-test). The average
RVIS for gene set 1 is 0.39 (range 0.11–0.67, 95% CI) whereas the
value for gene set 2 is −0.40 (range −0.77 to −0.03, 95% CI). As
expected, lower RVISs were observed for the documented disease
causal genes (gene set 2). The finding is consistent with low RVISs
in many OMIM genes (Petrovski et al., 2013). Nonetheless, the
positive average RVIS for gene set 1 is not surprising; among the
57 genes in set 1, 38 genes (67%) are classified as being high
tolerance.
Sub-classification of our 14 high SDS structure-disrupted vari-
ants yields 9 and 5 genes that are highly acceptable or tolerant of
mutations, respectively (Table 5). Although variants in genes with
low tolerance (negative RVISs) are more likely to be deleterious,
our SDS focuses at the variant level, and the structural analy-
sis potentially provides novel intuition that is not apparent from
any sequence- or gene-based analysis. Therefore, the indication
of many “high tolerance genes” in our dataset does not preclude
potential functional effects of specific variants. For this reason, we
performed in-depth literature searches on all 9 and 5 variants of
the 2 subgroups, and provide our inference of the likelihood that a
particular SNPmay contribute to the epilepsy disorders (Table 6).
Interestingly, we found that half (4 out of 9) of the SNPs in high
tolerance genes have potential to promote epilepsy. The propor-
tion is comparable (2 out of 5) for variants located in the low
tolerance genes. Of the 9 variants in high tolerance genes, one has
a structural feature that is compatible with those of neutral SNPs,
i.e., the variant alters a highly flexible protein site; therefore, we
disregarded it as a putative functional variant. Similar considera-
tion of the low tolerance genes suggests that just one, PPP1R27,
is likely to harbor a mutation that promotes epilepsy. This leads
to prioritization of 9 “high-priority putative functional variants
for epilepsy.” The locations of each of these variants with respect
to their protein 3D structures are shown in Figure 4, and each is
discussed below (variant numbering follows Table 5).
INDIVIDUAL ASSESSMENT OF PUTATIVE STRUCTURALLY
DELETERIOUS VARIANTS
Cys1359Arg in ABCA6
Cys1359 mutation is located in a buried site of ABCA6, a pro-
tein that plays roles inmacrophage lipid homeostasis (Figure 4A).
Despite the high SDS of this variant (score 5/7), it has not been
associated with diseases. The functionality of cysteine residue
depends largely on the protein structure and its cellular loca-
tion. For this instance of Cys to Arg change, it does not alter the
pattern of disulfide bonds, partly due to the rarity of this bond-
ing type within membrane proteins (Betts and Russell, 2003).
However, the C1359R mutation is still considered as a crucial
change (Grantham score 180, G 1.64 kcal/mol), especially
when the mutation occurs in the middle of protein domain.
Arg277Gly in ABHD14A
Arg277 is located on an exposed site of ABHD14A (Figure 4B).
Another member of this protein family, ABHD5, is thought
to be responsible for a rare genetic disorder called Chanarin-
Dorfman syndrome. This is the only variant among the 14 struc-
tural disrupted case SNPs that was not detected as “deleterious”
by any sequence-based algorithms (deleterious count 0/6), but
our SDS suggests it has potential impact on the protein (SDS
4/7). The wild type Arg227 residue has low sequence optimality
( −0.58 kcal/mol), a likely indicator that it has close proximity
to a catalytic site. Moreover, the Arg to Gly change is consid-
ered as an unfavorable substitution, especially when it occurs in a
Frontiers in Genetics | Statistical Genetics and Methodology April 2014 | Volume 5 | Article 82 | 10
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FIGURE 4 | 3D structures for the nine high-priority variants for epilepsy.
The nine high-priority variants for epilepsy include eight structural disrupted
variants (A–H) which locate in genes with high tolerance of polymorphisms
(Table 5) and one structural disrupted variant (M) which resides in a low
tolerance gene (Table 5). In all figures, mutated protein residues caused by
the SNPs are indicated with blue surface representations along with the
amino acid name (wild type) and residue index. Yellow surface
representations refer to predicted binding sites or catalytic sites, except in
(M) in which it represents a protein residue with close proximity to the
altered amino acid. Orange representations in (C) indicate the predicted
best conserved residue cluster on the protein surface. The substitution of
Ser150Cys in (E) adds one favorable hydrophobic residue (green surface
representation) to the core of the α/β horseshoe. The magenta sticks in (H)
represent the partner residue, Glu117, which forms a salt bridge with wild
type Arg137. This salt bridge is lost in the presence of mutant Cys at
position 137.
structured protein, as the lack of a side chain in Gly may diminish
proper protein folding or intermolecular interactions.
Arg404Gln in ALOX12
Arg404 is found in a buried site of ALOX12 (Figure 4C). Arg404
is in close proximity with the catalytic site of this protein and is
also predicted to be part of the protein patch for intermolecu-
lar interactions. The Arg404Gln substitution within this protein
is also predicted to cause a slight protein destabilization (G
0.90 kcal/mol), despite the acceptable Grantham substitution
score (<100). We suspect the variant may play roles in epilepsy
implication, since a link between its substrate (arachidonic acid)
and seizure susceptibility had been proposed (Cole-Edwards and
Bazan, 2005).
Ile463Thr in DDX52
Ile463 is located in a buried site of DDX52 (Figure 4D). A
study of seizure susceptibility in Drosophila discovered that a
gain-of-function mutation in the maleless helicase gene can sup-
press seizure susceptibility in bang-sensitive Drosophila mutants
(Kuebler et al., 2001). The Ile463Thr mutation in this pro-
tein affects the structural integrity of the protein since it is
detected as a SC, consistent with its destabilization effect (G
1.37 kcal/mol).
Ser150Cys in EYPC
The Ser150Cys variant is located in the core of the leucine-
rich repeat (LRR) structural motifs of EYPC (Figure 4E). Several
disulfide bonds are formed between cysteine clusters that flank
Frontiers in Genetics | Statistical Genetics and Methodology April 2014 | Volume 5 | Article 82 | 14
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the LRRs, providing additional structural support, but no changes
of disulfide bonds or hydrogen bonds appear in the mutated
protein. Ser150Cys has minimal impact on protein stability
(G = −0.41 kcal/mol), and while the substitution induces
a large physico-chemical change (Grantham score ≥ 100), the
substitution is considered neutral if located in α/β protein (Xu
et al., 2010). Indeed, we observed Ser150Cys added one favorable
hydrophobic residue to the core of the α/β horseshoe. Despite
its high SDS (4/7), we consider it unlikely that this variant
contributes to any disorders.
Asp506Gly in HELB
Asp506 is situated in a buried site of HELB (Figure 4F) and sev-
eral of its features are predicted to interfere with ligand binding.
First, wild type Asp506 has an exceptionally low sequence opti-
mality value ( − 4.14 kcal/mol). Second, wild type Asp506 is
predicted to be a highly flexible site by three parameters, although
the values are not extreme. Third, the Asp506Gly substitution is
predicted to destabilize the protein (G 1.40 kcal/mol). These
characteristics coincide with a recent mutagenesis experiment
that proves Asp506 is part of a binding motif, and the mutation
of D506A induces loss of substrate binding when associated with
E499A and D510A (Guler et al., 2012). Study of another human
DNA helicase, Twinkle, demonstrated that two missense muta-
tions were detected in patients with a wide range of psychiatric
symptoms, including severe epileptic encephalopathy, possibly
due to inefficient recovery frommolecular stress (Lonnqvist et al.,
2009). HELB Asp506 is thus particularly interesting for further
assessment of a role in epilepsy.
Leu43Val in IAH1
Leu43 is located at a buried site in IAH1, although it lies far from
the substrate binding site (Figure 4G). The protein is of interest
given that many antiepileptic drugs are potent enzyme inducers
and inhibitors of the cytochrome P450 system, which affects lipid
and glucose metabolisms, as well as evidence that increased lipase
level is one of the side effects of anti-psychotic and anti-epileptic
drugs (Voudris et al., 2004, 2006). Substitution of Leu to Val is
quite favorable in all protein folding types (Xu et al., 2010), but
Leu43Val in this protein is suspected to reduce protein stability
(G 2.06 kcal/mol). A plausible explanation may be that this
protein is highly structured, comprising only a few loop residues.
The turn regions may play an essential role in bringing together
and enabling or allowing interactions between regular secondary
structure elements.
Arg137Cys in NMUR1
Arg137 is situated in the central cavity of NMUR1 (Figure 4H).
The presence of the a mutant Cys at position 137 diminishes the
stabilizing salt bridge between wild type Arg137 and Glu117, and
results in a decrease in protein stability (G 1.83 kcal/mol). The
gene has no known associations with any diseases.
Ile112Met in PPP1R27
Ile112 is found at a buried site of PPP1R27 (Figure 4M). A
study of a similar protein, PPP1R3C, identified one missense
mutation that may lead to a mild phenotype in Lafora disease—
a teenage onset epilepsy disorder (Guerrero et al., 2011). In
addition, protein phosphatase 1 (PP1) was identified as a member
of long term potentiation (PTP) pathway in epileptogenesis and
epilepsy (KEGG: map04720) (Kanehisa and Goto, 2000; Lukasiuk
and Pitkanen, 2012). Other genes in this pathway mostly reg-
ulate neurotransmission and ion channel receptors. The Ile to
Met substitution is quite favorable both in general (Grantham
score < 100) and in distinct types of protein folding (Xu et al.,
2010). However, the longer aliphatic side chain of Met creates
steric clashes with Ala104 of an adjacent helical region. This sin-
gle point mutation is predicted to destabilize the protein (G
1.41 kcal/mol).
STRUCTURAL DISRUPTION SCORE CORRELATES WITH
SEQUENCE-BASED DELETERIOUS SCORE
Finally, we tested whether the SDS correlates with measures not
used to construct the score itself. We performed an additional
sequence-based deleterious prediction of case SNPs using Condel:
a weighted score that integrates the output of five tools (Gonzalez-
Perez and Lopez-Bigas, 2011), three of which were used in our
analysis. There is a significant positive correlation between our
SDS and the Condel score (p-value 0.0342, n = 30). The trend
persists after removing the sequence-based deleterious scores
from SDSs of 16 variants (the variants have deleterious count ≥ 4
out of 6), although the significance in correlation is reduced to a
marginal level (p-value 0.0717). In addition, we performed a sim-
ilar analysis by sequentially removing one SDS component from
the total score, and found the significantly positive correlation
between SDS and Condel is maintained (Table 7). The weak-
est structure-based parameter among all of the SDS components
is the classification of buried vs. exposed site using RSA. After
removing this indicator from 15 variants, we did not detect any
correlation between the two measures (p-value 0.13). Note that
this analysis is complicated by the small sample sizes. Nonetheless,
the finding supports our expectation that although the deleteri-
ous count is one of the major components for constructing our
SDS, the remaining non-conventional deleteriousness parame-
ters also have substantial impact on the overall missense variant
evaluation.
DISCUSSION
CURRENT PERSPECTIVES IN PRIORITIZATION OF EPILEPSY VARIANTS
The evaluation and prioritization of candidate case variants
is particularly difficult when the disorder involves a dissimi-
lar set of genes, as is the case for epilepsy disorders, which are
now known to involve diverse molecular pathways (Noebels,
2003; Garofalo et al., 2012). The classic epilepsy genes (ion
channel genes/regulatory genes, neurotransmitter genes/receptor
genes/regulatory genes, genes that disrupt cortical circuits, and
genes that lower the convulsion stimuli) rarely present in genomic
data from sequencing studies. This may be because the classi-
cal epilepsy mutations are Mendelian, whereas exome sequenc-
ing likely targets more polygenic cases, noting that only 1% of
epilepsy disorders are inherited in a Mendelian manner (Cavalleri
and Delanty, 2012).
Ferraro et al. (2012) highlighted how daunting the task is
for epilepsy when they exemplified some factors in the design
of cohort studies that influences the discovery of true positive
epileptic variants: the selection of cases (presence/absence of the
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Table 7 | Step-wise analysis for correlation of SDS and Condel score.
SDS parameters R2 of P-value of # of variants
linear fit correlation affected by the
revised SDS†
All SDS 0.1504 0.0342** none
SDS-high deleterious count 0.1112 0.0717* 16
SDS-large amino acid change 0.1508 0.0340** 5
SDS-induce gly/Pro change 0.1308 0.0496** 7
SDS-locate in buried site 0.0782 NS (p = 0.1344) 15
SDS-locate on protein patch 0.1629 0.0270** 3
SDS-locate in protein domain 0.2093 0.0110** 25
SDS-reduce protein stability 0.1243 0.0560* 20
Initial SDS includes 7 parameters, described in Table 4; the maximum SDS for
each variant is 7. The revised SDS calculates the score by exclude one SDS
component at a time; the maximum revised score for a variant equals 6.
†The full dataset has 30 missense variants. All data points were used to test for
a correlation between SDS and Condel score. When an SDS component was
removed during the step-wise analysis, the SDSs for some numbers of variants
were affected, i.e., the excluded parameter was applicable to the variant. For
such cases, the correlation analysis was performed with all of the 30 data points,
minus the number of exclusions indicated in the last column. Significant p-values
are designated with “**” and “*” for α = 0.05 and α = 0.10, respectively. Non-
significant test statistics are labeled with NS, followed by the correspondent
p-value.
cause of symptoms), the seizure types (determine the amount
of genetic influences), the patient profiles (age at onset, gen-
der, characters of seizure incidences, etc.), and the assumption
of genetic patterns (common variant effects, rare variant effects,
or a combination of both) (Ferraro et al., 2012). Some authors
are starting to incorporate disease information as prior knowl-
edge in the probabilistic evaluation of candidate causal SNPs
(Yandell et al., 2011; Sifrim et al., 2013; Robinson et al., 2014),
but the scarcity of knowledge related to epilepsy genes limits this
approach. Indeed, we found that the genes in our dataset are
somewhat poorly understood and their disease contributions are
largely unknown.
In addition to SNPs, structural variations have been shown
to associate with epilepsy genetics. Jia et al. (2011) used step-
wise enrichment analysis of protein-protein interactions to derive
a molecular network of 20 high priority candidate genes linked
to copy number variation (Jia et al., 2011). Interestingly, the
genes do not overlay with the 68 homozygous nsSNP-containing
genes in our dataset [but they do overlap with 4/1604 genes
that harbor heterozygous variants: (Heinzen et al., 2012)]. An
independent comparison with nine genes that harbor de novo
mutations (identified from trios—unaffected parents and their
affected child) also found no overlap (Epi4k Consortium and
Epilepsy Phenomegenome Project, 2013).
Consequently, we cannot be sure that any of the variants dis-
cussed in this article are truly causal for epilepsy. However, the
variant prioritization scheme does suggest a reduced number
of candidates which, on the basis of careful curation of pro-
tein structure, might be taken forward for targeted experimental
manipulation and assessment of biological function in cell lines
or model organisms.
KEY FINDINGS
We have developed a structure-based variant analysis protocol
that evaluates the effects of missense mutations with respect to
their predicted effects on protein features, such as solvent accessi-
bility, stability, and flexibility. Replicated trends for putative case
SNPs to have aberrant structural features that more closely match
those of established disease mutations in the same proteins, than
to those of neutral polymorphisms, establish the potential util-
ity of this approach as an orthogonal protocol to sequence-based
assessment of deleteriousness.
Starting with 71 genes harboring putative case SNPs from an
exome sequencing study of epilepsy disorders (Heinzen et al.,
2012), we were able to perform the assessments on 57 gene prod-
ucts. Presumably only a fraction of these are actually causal, so
our expectation was simply that the distribution of risk scores
may be shifted from neutral toward disease-associated. Several
features were observed to classify SNPs into two groups: puta-
tive functional variants, or presumably neutral variants, and a
composite risk score based on summation of these features high-
lighted nine putative functional variants, from thirty exclusive
missense mutations whose protein 3D structures are available.
Although none of these has been previously linked to epilepsy
disorders, detailed case-by-case analysis strongly suggests that
several should be prioritized for further functional evaluation.
Although our structure-based analysis only captured a fraction
of variant residues due to the limited availability of 3D structures
(Table 1), we show that 44, 32, and 75%, of case, negative, and
positive variants from the first gene set are amenable to structure-
based predictions. The equivalent percentages for set 2 genes are
49, 37, and 51%, respectively. More importantly, we were able to
represent 84% of the proteins in our first set, and 86% in the
second set, despite the difficulty in generating high quality struc-
tures. Our preliminary analyses suggest that it is not necessary
to have structural data for all variants in order to construct the
SDS. Since the sequence-based predictions of variants with struc-
ture data are similar to those obtained for all SNPs in the dataset
(data not shown), we are confident that the conclusions from our
structure-based variant assessment protocol can be extended to
the complete SNP pools in each of the two gene sets.
With our combined sequence- and structure-based analysis
pipeline, we discovered that some features are predominantly
found among negative or positive SNPs. Structure-based param-
eters contribute as much as 50% of the features that differentiate
the two types of variants. There are several key observations from
our feature enrichment analysis. First, we noticed seven common
characteristics that are predominantly found in the positive con-
trol SNPs, regardless of the set of genes. SNPs with strong effects
are those that: have deleterious count≥ 4, have Grantham score≥
100, induce glycine or proline changes, locate in protein domains,
in buried sites, or on conserved protein patches, and destabi-
lize the protein. Second, variants with neutral effects (negative
SNPs) have a few strong enriched features. In gene set 1, we found
negative SNPs are more likely to be in conformationally flexible
sites. A similar feature was detected in gene set 2, in which non-
damaging SNPs are mostly highly dynamic sites. An additional
distinctive characteristic of the negative SNPs in gene set 1 is that
they tend to affect highly conserved residues. This finding appears
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to be counter intuitive; we suspected that this unique observation
seems to be an exception for this particular gene group.
STUDY LIMITATIONS
A primary limitation of our approach is the requirement for
homology models that support computational prediction of
structural characteristics. Specifically, only 18/68 proteins had at
least partial experimental structures, so homologous templates
were used in most cases. These were not available for just 9%
of the proteins (n = 6), but the retained models did not cover
the disrupted site for another 56% (36/68 variant sites), and 24
of the potentially disrupted proteins are larger than 1000 amino
acids, which also presents additional challenges for buildingmod-
els and satisfying quality settings. Nevertheless, by restricting the
modeling to domains, we were able to model 84% of the 68
candidate genes (covering 44, 32, and 75%, of case, negative,
and positive variants). This is a clear improvement on the auto-
mated pipelines used in training algorithms such as PolyPhen2.
We also ensured that the quality of the models was validated
wherever possible, which also introduces an intensive manual
curation requirement into the analytical pipeline, requiring some
knowledge with methods that most genomicists are not familiar
with.
An analytical limitation is that the size of the dataset is rela-
tively small, since only one variant per gene was studied, and just
68 proteins were available to begin with. Since these are struc-
turally diverse, it is likely that different aspects of protein structure
are affected and the probability of enrichment for any one struc-
tural feature is correspondingly reduced. While approximately
three quarters of amino acid changes leading to Mendelian dis-
eases consistently induce protein destabilization (Yue et al., 2014),
the structural consequences of missense variants in complex dis-
eases such as the epilepsy disorders are likely to be of a more
diverse nature.
STUDY INNOVATIONS
The SDS offers a novel strategy for genomic profiling of variants
that have uncertain but likely weakly deleterious function. It com-
bines similar instances of variants with respect to their predicted
impact on aspects of protein structure, allowing joint assessment
of the impact of the variants as a class on biological function.
Instead of evaluating each variant one by one, SDS provides a
ranking that might be used to guide downstream experimental
and/or clinical evaluations.
Other studies using structural biology approaches to exam-
ine the variant effects have considered a large number of variants
per gene, facilitating direct contrasts of variant characteristics and
predictions for individual genes (Dybowski et al., 2011) or genes
with similar structures/functions (Jordan et al., 2011; Izarzugaza
et al., 2013). The genomic data that we started with is rela-
tively small by comparison. However, we provide an alternative
structure-based approach that can accommodate the small num-
ber of variants expected from exome sequencing samples as well
as the large diversity of gene functions they will typically generate.
Most importantly, our SDS score implementation assures that
case variants share similar characteristics as those observed in
causal variants, but not neutral variants known to reside in the
same proteins. We have validated the findings in a replication
dataset, and show how the approach can be used as a unique solu-
tion to prioritizing case variants in unrelated genes. Though not
providing a guarantee of disrupted function, the score should be
considered as a complementary approach to existing sequence-
based deleteriousness prediction.
CONCLUSION
Using the list of enriched features, we concluded that this novel
structure-based assessment protocol for missense variant dele-
teriousness has a potential to determine high-priority candidate
variants suitable for experimental validations. The analysis may
prove to be useful, particularly when traditional sequence-based
predictions are inconclusive. An important question is whether
the same structural attributes differentiate neutral and functional
variants for different categories of diseases.
Because our study employed large numbers of external
resources (variant predictions, gene information, 3D structure
modeling and quality controls, and sequence- and structure-
based predictions), the analysis pipeline presented here is not
readily automated. Aspects of it are in theory readily generaliz-
able to all classes of proteins, and once all the above steps have
been accomplished, the variant deleteriousness structure-based
predictions could be effectively populated into a database. After
that labor-intensive step is completed, the SDS for any variants in
a dataset may be computed and retrieved virtually by combining
the predictions for the genes specific for the study.
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